Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
BKD vs CCRN vs HCSG vs HCA vs THC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
BKD vs CCRN vs HCSG vs HCA vs THC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $3.22B | $423M | $1.60B | $95.95B | $17.01B |
| Revenue (TTM) | $3.11B | $761M | $1.84B | $75.60B | $21.45B |
| Net Income (TTM) | $-205M | $-99M | $59M | $6.78B | $1.70B |
| Gross Margin | 14.3% | 18.2% | 13.3% | 41.5% | 42.8% |
| Operating Margin | 1.4% | -0.9% | 3.0% | 15.8% | 16.1% |
| Forward P/E | — | 133.8x | 20.8x | 14.2x | 10.9x |
| Total Debt | $6.66B | $2M | $25M | $50.20B | $13.17B |
| Cash & Equiv. | $279M | $109M | $161M | $1.04B | $2.88B |
BKD vs CCRN vs HCSG vs HCA vs THC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Brookdale Senior Li… (BKD) | 100 | 370.4 | +270.4% |
| Cross Country Healt… (CCRN) | 100 | 215.7 | +115.7% |
| Healthcare Services… (HCSG) | 100 | 93.3 | -6.7% |
| HCA Healthcare, Inc. (HCA) | 100 | 401.5 | +301.5% |
| Tenet Healthcare Co… (THC) | 100 | 892.1 | +792.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BKD vs CCRN vs HCSG vs HCA vs THC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BKD is the #2 pick in this set and the best alternative if defensive is your priority.
- Beta 0.67, current ratio 3.62x
- +105.1% vs CCRN's -5.4%
CCRN is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
HCSG ranks third and is worth considering specifically for growth exposure.
- Rev growth 7.1%, EPS growth 52.8%, 3Y rev CAGR 2.8%
- 7.1% revenue growth vs CCRN's -21.6%
HCA carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- 9.0% margin vs CCRN's -13.0%
- Beta 0.29 vs HCSG's 1.12
- 0.7% yield; 5-year raise streak; the other 4 pay no meaningful dividend
THC is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 5.2% 10Y total return vs HCA's 450.5%
- PEG 0.33 vs HCA's 0.67
- Lower P/E (10.9x vs 14.2x), PEG 0.33 vs 0.67
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.1% revenue growth vs CCRN's -21.6% | |
| Value | Lower P/E (10.9x vs 14.2x), PEG 0.33 vs 0.67 | |
| Quality / Margins | 9.0% margin vs CCRN's -13.0% | |
| Stability / Safety | Beta 0.29 vs HCSG's 1.12 | |
| Dividends | 0.7% yield; 5-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +105.1% vs CCRN's -5.4% | |
| Efficiency (ROA) | 11.3% ROA vs CCRN's -19.8%, ROIC 19.9% vs -0.9% |
BKD vs CCRN vs HCSG vs HCA vs THC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
BKD vs CCRN vs HCSG vs HCA vs THC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
THC leads in 2 of 6 categories
HCA leads 1 • BKD leads 1 • HCSG leads 1 • CCRN leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
THC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 99.4x CCRN's $761M. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to CCRN's -13.0%. On growth, HCA holds the edge at +6.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3.1B | $761M | $1.8B | $75.6B | $21.5B |
| EBITDAEarnings before interest/tax | $384M | $9M | $72M | $15.5B | $4.3B |
| Net IncomeAfter-tax profit | -$205M | -$99M | $59M | $6.8B | $1.7B |
| Free Cash FlowCash after capex | $56M | $41M | $139M | $7.7B | $3.3B |
| Gross MarginGross profit ÷ Revenue | +14.3% | +18.2% | +13.3% | +41.5% | +42.8% |
| Operating MarginEBIT ÷ Revenue | +1.4% | -0.9% | +3.0% | +15.8% | +16.1% |
| Net MarginNet income ÷ Revenue | -6.6% | -13.0% | +3.2% | +9.0% | +7.9% |
| FCF MarginFCF ÷ Revenue | +1.8% | +5.4% | +7.6% | +10.2% | +15.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.0% | -100.0% | +6.6% | +6.7% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +89.7% | -6.0% | +175.0% | +44.6% | +87.6% |
Valuation Metrics
THC leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 12.5x trailing earnings, THC trades at a 54% valuation discount to HCSG's 27.5x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs HCA's 0.72x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $3.2B | $423M | $1.6B | $95.9B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $9.6B | $317M | $1.5B | $145.1B | $27.3B |
| Trailing P/EPrice ÷ TTM EPS | -12.21x | -4.47x | 27.54x | 15.12x | 12.53x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 133.84x | 20.83x | 14.19x | 10.94x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.72x | 0.38x |
| EV / EBITDAEnterprise value multiple | 25.53x | 23.75x | 22.38x | 9.37x | 6.34x |
| Price / SalesMarket cap ÷ Revenue | 1.03x | 0.40x | 0.87x | 1.27x | 0.80x |
| Price / BookPrice ÷ Book value/share | — | 1.31x | 3.19x | — | 1.97x |
| Price / FCFMarket cap ÷ FCF | — | 10.55x | 11.49x | 12.47x | 6.72x |
Profitability & Efficiency
HCA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
THC delivers a 19.6% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $-235 for BKD. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), HCSG scores 7/9 vs BKD's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -234.5% | -27.1% | +11.8% | — | +19.6% |
| ROA (TTM)Return on assets | -3.4% | -19.8% | +7.3% | +11.3% | +5.7% |
| ROICReturn on invested capital | +0.2% | -0.9% | +9.0% | +19.9% | +13.2% |
| ROCEReturn on capital employed | +0.3% | -0.8% | +7.7% | +27.0% | +13.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 7 | 7 | 7 |
| Debt / EquityFinancial leverage | — | 0.01x | 0.05x | — | 1.47x |
| Net DebtTotal debt minus cash | $6.4B | -$106M | -$136M | $49.2B | $10.3B |
| Cash & Equiv.Liquid assets | $279M | $109M | $161M | $1.0B | $2.9B |
| Total DebtShort + long-term debt | $6.7B | $2M | $25M | $50.2B | $13.2B |
| Interest CoverageEBIT ÷ Interest expense | 0.19x | -1.39x | 33.02x | 5.37x | 4.28x |
Total Returns (Dividends Reinvested)
BKD leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $7,746 for CCRN. Over the past 12 months, BKD leads with a +105.1% total return vs CCRN's -5.4%. The 3-year compound annual growth rate (CAGR) favors BKD at 50.3% vs CCRN's -17.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +25.0% | +62.4% | +28.6% | -8.6% | -2.7% |
| 1-Year ReturnPast 12 months | +105.1% | -5.4% | +55.8% | +19.7% | +27.4% |
| 3-Year ReturnCumulative with dividends | +239.7% | -44.3% | +48.6% | +57.4% | +178.5% |
| 5-Year ReturnCumulative with dividends | +85.2% | -22.5% | -21.1% | +109.7% | +190.4% |
| 10-Year ReturnCumulative with dividends | -26.0% | -10.5% | -26.8% | +450.5% | +523.4% |
| CAGR (3Y)Annualised 3-year return | +50.3% | -17.7% | +14.1% | +16.3% | +40.7% |
Risk & Volatility
Evenly matched — HCSG and HCA each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than HCSG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCSG currently trades 91.5% from its 52-week high vs HCA's 77.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.67x | 0.78x | 1.12x | 0.29x | 0.71x |
| 52-Week HighHighest price in past year | $17.00 | $14.99 | $24.39 | $556.52 | $247.21 |
| 52-Week LowLowest price in past year | $6.07 | $7.43 | $12.66 | $330.00 | $146.60 |
| % of 52W HighCurrent price vs 52-week peak | +79.7% | +87.3% | +91.5% | +77.1% | +78.5% |
| RSI (14)Momentum oscillator 0–100 | 54.0 | 53.1 | 61.8 | 30.8 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 3.3M | 552K | 676K | 1000K | 1.2M |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: BKD as "Buy", CCRN as "Hold", HCSG as "Hold", HCA as "Buy", THC as "Buy". Consensus price targets imply 38.1% upside for THC (target: $268) vs -18.9% for CCRN (target: $11). HCA is the only dividend payer here at 0.69% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $17.67 | $10.61 | $24.50 | $527.45 | $268.00 |
| # AnalystsCovering analysts | 12 | 14 | 15 | 46 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +0.7% | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | 20 | 5 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | $2.94 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | +1.6% | +3.9% | +10.5% | +8.4% |
THC leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). HCA leads in 1 (Profitability & Efficiency). 1 tied.
BKD vs CCRN vs HCSG vs HCA vs THC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BKD or CCRN or HCSG or HCA or THC a better buy right now?
For growth investors, Healthcare Services Group, Inc.
(HCSG) is the stronger pick with 7. 1% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Tenet Healthcare Corporation (THC) offers the better valuation at 12. 5x trailing P/E (10. 9x forward), making it the more compelling value choice. Analysts rate Brookdale Senior Living Inc. (BKD) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BKD or CCRN or HCSG or HCA or THC?
On trailing P/E, Tenet Healthcare Corporation (THC) is the cheapest at 12.
5x versus Healthcare Services Group, Inc. at 27. 5x. On forward P/E, Tenet Healthcare Corporation is actually cheaper at 10. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — BKD or CCRN or HCSG or HCA or THC?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.
4%, compared to -22. 5% for Cross Country Healthcare, Inc. (CCRN). Over 10 years, the gap is even starker: THC returned +523. 4% versus HCSG's -26. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BKD or CCRN or HCSG or HCA or THC?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus Healthcare Services Group, Inc. 's 1. 12β — meaning HCSG is approximately 292% more volatile than HCA relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — BKD or CCRN or HCSG or HCA or THC?
By revenue growth (latest reported year), Healthcare Services Group, Inc.
(HCSG) is pulling ahead at 7. 1% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, HCA leads at 7. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BKD or CCRN or HCSG or HCA or THC?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — THC leads at 82. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BKD or CCRN or HCSG or HCA or THC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Tenet Healthcare Corporation (THC) trades at 10. 9x forward P/E versus 133. 8x for Cross Country Healthcare, Inc. — 122. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for THC: 38. 1% to $268. 00.
08Which pays a better dividend — BKD or CCRN or HCSG or HCA or THC?
In this comparison, HCA (0.
7% yield) pays a dividend. BKD, CCRN, HCSG, THC do not pay a meaningful dividend and should not be held primarily for income.
09Is BKD or CCRN or HCSG or HCA or THC better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, HCSG: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BKD and CCRN and HCSG and HCA and THC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BKD is a small-cap quality compounder stock; CCRN is a small-cap quality compounder stock; HCSG is a small-cap quality compounder stock; HCA is a mid-cap deep-value stock; THC is a mid-cap deep-value stock. HCA pays a dividend while BKD, CCRN, HCSG, THC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.